FindTrial
Sign In

ALBI serves as a predictive factor of tolerability of patients with Stage II/III gastric cancer to adjuvant S-1 monotherapy after curative gastrectomy

ALBI serves as a predictive factor of tolerability of patients with Stage II/III gastric cancer to adjuvant S-1 monotherapy after curative gastrectomy - ALBI predicts tolerability of adjuvant S-1 monotherapy

Status
Unknown
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-jRCT1090220373
Enrollment
Unknown
Registered
2018-08-03
Start date
2005-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Intervention type: Name of intervention:S-1 Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application: Dose per administration:40-60 40-60 mg Dosing frequen

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients started S-1 adjuvant monotherapy within 6 weeks after surgery.

Exclusion criteria

Exclusion criteria: Patients received adjuvant chemotherapy with other drugs, as well as those who experienced recurrence within 6 months after gastrectomy.

Design outcomes

Primary

MeasureTime frame
To identify a predictive factor for tolerability of postoperative adjuvant S-1 monotherapy for gastric cancer (GC)—

Contacts

Public ContactTakashi Miwa

Nagoya University Graduate School of Medicine

takashimiwa@med.nagoya-u.ac.jp+81-52-744-2249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026